{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:32:29Z","timestamp":1786649549639,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Currently, the recommended management in stage IVA bladder cancer is platinum-based chemotherapy followed by maintenance immunotherapy in those with no evidence of disease progression. Consolidative surgery may be considered in selected cases after chemotherapy. However, consolidative radiotherapy and consolidative local treatment after second-line systemic therapy are rarely reported. We present the case of a 59-year-old man who was found to have muscle invasive urothelial carcinoma of the bladder with distant metastases limited to para-aortic nodes and offered consolidative extended field chemoradiation therapy encompassing bladder, pelvis, and para-aortic areas after an excellent response to second-line chemotherapy with paclitaxel and carboplatin. The patient is systemically well with no evidence of disease progression at 20 months of follow-up. Aggressive multimodality management involving consolidative radiation therapy may be attempted to improve the disease control in a small subset with stage IVA urothelial bladder carcinoma even after first-line systemic therapy, especially in the setting of nonaffordability to immune check point inhibitors.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_2393_23","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:00:28Z","timestamp":1751713228000},"page":"725-729","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Extended field chemoradiation in M1a bladder carcinoma: A case report"],"prefix":"10.4103","volume":"21","author":[{"given":"Kannan","family":"Periasamy","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Oncology, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Urology, Advanced Urology Centre, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vigneshwaran","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"R1-20250707","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20250707","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer:ESMO clinical practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"59.e1","DOI":"10.1016\/j.urolonc.2015.08.012","article-title":"Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy:The M. D. Anderson Cancer Center Experience","volume":"34","author":"Ho","year":"2016","journal-title":"Urol Oncol"},{"key":"R5-20250707","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/BLC-180186","article-title":"The outcome of post-chemotherapy retroperitoneal lymph node dissection in patients with metastatic bladder cancer in the retroperitoneum","volume":"5","author":"Liu","year":"2019","journal-title":"Bladder Cancer"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejso.2008.07.001","article-title":"Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only","volume":"35","author":"Vries","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.radonc.2018.02.013","article-title":"An atlas to aid delineation of para-aortic lymph node region in cervical cancer:Design and validation of contouring guidelines","volume":"127","author":"Keenan","year":"2018","journal-title":"Radiother Oncol"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","article-title":"Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:European Organization for Research and Treatment of Cancer Protocol no. 30924","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"R11-20250707","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"R12-20250707","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"R13-20250707","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/cncr.21370","article-title":"Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma","volume":"104","author":"Vaishampayan","year":"2005","journal-title":"Cancer"},{"key":"R14-20250707","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdq398","article-title":"Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer:Short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20\/99","volume":"22","author":"Albers","year":"2011","journal-title":"Ann Oncol"},{"key":"R15-20250707","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0302-2838(02)00060-X","article-title":"Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy","volume":"41","author":"Gschwend","year":"2002","journal-title":"Eur Urol"},{"key":"R16-20250707","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2013.08.082","article-title":"Induction chemotherapy followed by surgery in node positive bladder cancer","volume":"83","author":"Meijer","year":"2014","journal-title":"Urology"},{"key":"R17-20250707","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2019.07.017","article-title":"The intensity-modulated pelvic node and bladder radiotherapy (IMPART) trial:A phase II single-centre prospective study","volume":"32","author":"Tan","year":"2020","journal-title":"Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2393_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:55:17Z","timestamp":1786647317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2393_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2393_23","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2023-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}